Home  Index  News

 Existing drug effective at preventing onset of type 1 diabetes in 60% of patients
A drug commonly used to control high blood pressure may also help prevent the onset of type 1 diabetes in up to 60 percent of those at risk for the disease, according to researchers at the University of Colorado Anschutz Medical Campus and the University of Florida in Gainesville.

Kratom-containing Products by Triangle Pharmanaturals: Mandatory Recall - Risk of Salmonella
FDA issued a mandatory recall order for all food products containing powdered kratom manufactured, processed, packed, or held by Triangle Pharmanaturals LLC, after several were found to contain salmonella. The agency took this action after the company failed to cooperate with the FDA’s request to conduct a voluntary recall

FDA approves Sorrento’s non-opioid painkiller patch
SHARE The US Food and Drug Administration (FDA) has granted Sorrento Therapeutics subsidiary Scilex approval for its non-opioid pain relieving patch ZTlido.

Novartis to partner with Pear to develop digital therapeutics apps
Novartis has announced that it will collaborate with Pear Therapeutics to develop mobile apps for patients with schizophrenia and multiple sclerosis (MS)

Celgene’s MS drug rejected by FDA due to insufficient data
Celgene has received a Refusal to File letter from the US Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for ozanimod, a drug candidate for the treatment of relapsing forms of multiple sclerosis (MS).

US green light for Gilead’s HIV combo
Gilead’s new combination therapy Biktarvy has been approved by the US Food and Drug Administration for the treatment of HIV.

Scientists discover way to halt breast cancer spread
Scientists have uncovered a key mechanism that facilitates the spread of breast cancer cells, and thus a potential target for new therapeutic approaches in the fight against the disease.

New enzyme replacement therapy to treat rare genetic disorder alpha-mannosidosis in children and adults
Lamzede is first treatment of this disease recommended for marketing authorisation

In recent years Iran branch of Vitane was established with main focus on manufacturing biologics, special treatment and orphan drugs. The production site of the company will be opened in this year with some products which are entered to domestic market through contract manufacturing. CONTACT US »
ویتان فارمد
With in headquarters in Germany , the company has entered into manufacturing alliances with leading pharmaceutical manufacturers in the U.S., Europe, Asia and Middle East.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to VITANE PHARMED Inc.